nature nature communications articles article Article Open access Published: 13 July 2024 GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney diseaseHeng-Chih Pan,
但需注意的是，本次研究数据来自 VA 电子健康记录，研究人员未对比不同 GLP-1 药物的类内效应，且研究对象主要为年龄较大的白人退伍军人，结果可能不适用于其他人群 。论文链接：https://www.nature.com/articles/s41591-024-03412-w （转自：新康界）
1. https://www.pnas.org/doi/10.1073/pnas.79.2.345 2. https://www.nature.com/articles/302716a0 3. https://www.nature.com/articles/304368a0 4. https://doi.org/10.1016/S0021 5. https://www.jci.org/articles/view/1...
[6] Obesity drugs have another superpower: taming inflammation,Retrieved Feb5, 2024 from https://www.nature.com/articles/d41586-024-00118-4?utm_medium=Social&utm_campaign=nature&utm_source=Twitter#ref-CR8 [7] Meyer...
nature scientific reports articles article Article Open access Published: 22 August 2017 GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptorJoseph Fusco, Xiangwei Xiao, Krishna Prasadan, Qingfeng Sheng, Congde Chen, Yung-Ching Ming & George Gittes ...
^https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571243/ ^Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry RG, Goodpaster BH, Roubenoff R. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Dia...
参考资料：[1]https://med.stanford.edu/news/all-news/2024/08/diet-taurine-weight.html [2]https://www.nature.com/articles/s41586-024-07801-6 [3]https://brainresilience.stanford.edu/news/qa-unlocking-secrets-taurine-obesity-control [4]https://data.worldobesity.org/publications/?cat=22 [5]...
垮脸只是司美格鲁肽导致的大幅度减肌问题所衍生的后果之一。研究显示,司美格鲁肽受试者减掉的体重中近40%为肌肉。 在司美格鲁肽减重适应症国内获批的同时,司美脸(Ozempic Face)也在欧美刷屏,多位名人惊现面部凹陷,减肥导致大量肌肉流失,加速面容衰老。同时身体其他部位同样也可能会出现皮肤下垂和类似于“妊娠纹”的...
原文链接 Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker prize for pioneering work on GLP-1 https://www.jci.org/articles/view/186225 生物制品微信群! 请注明:姓名+研究方向! 版 权 声 明
诺和诺德Amylin+司美格鲁肽联合治疗已经进入三期临床阶段,但也并没有放弃多靶点技术路线,GLP-1R/GIPR双靶点激动剂也进入二期临床阶段。此外,诺和诺德还在积极开发Amycretin,为GLP-1R/胰淀素受体双靶点激动剂。 Armstrong 2024年3月22日,诺和诺德在Clinicaltrials.gov网站上注册了的NN0519-0130用于减重、降糖的二期临床试...